Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy

Vascular endothelial growth factor A (VEGF-A) inhibition with pazopanib is an approved therapy for sarcomas, but likely results in compensatory pathways such as upregulation of hypoxia inducible factor 1α (HIF-1α). In addition, cancer stem-like cells can preferentially reside in hypoxic regions of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Changhwan, Chang, Kevin K., Lee, Jun Ho, Tap, William D., Hart, Charles P., Simon, M. Celeste, Yoon, Sam S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189991/
https://www.ncbi.nlm.nih.gov/pubmed/27374091
http://dx.doi.org/10.18632/oncotarget.10212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189991/
https://www.ncbi.nlm.nih.gov/pubmed/27374091
http://dx.doi.org/10.18632/oncotarget.10212

Ejemplares similares